CLINICAL TRIALS PROFILE FOR NEURACEQ

All Clinical Trials for NEURACEQ

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04576793 ↗	Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease	Recruiting	National Institute on Aging (NIA)	Phase 2	2020-11-17	The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease to participate. This includes patients with either: - Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties - Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties - Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties - The investigators are also enrolling older adults with normal visual, language, and memory function.
NCT03744312 ↗	Imaging Inflammation in Alzheimer's Disease With 11C-ER176	Enrolling by invitation	William Charles Kreisl	Phase 1/Phase 2	2018-09-10	This study is being done to learn about inflammation in the brain of those with Alzheimer's disease (AD). The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. Both patients (with either mild cognitive impairment (MCI) or Alzheimer's disease) and healthy controls (participants without memory complaints or impairment) will be included in this study.
NCT03779815 ↗	Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography	Completed	Ulsan University Hospital	N/A	2018-08-20	[18F]Florbetaben PET/CT imaging will noninvasively assess amyloid deposition in systemic amyloidosis.
NCT02831283 ↗	Imaging Inflammation in Alzheimer's Disease	Enrolling by invitation	National Institute on Aging (NIA)	Phase 2	2016-06-01	This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and do tests to measure the participants' memory and thinking.
NCT02831283 ↗	Imaging Inflammation in Alzheimer's Disease	Enrolling by invitation	William Charles Kreisl	Phase 2	2016-06-01	This study is being done to learn about inflammation and amyloid in Alzheimer's disease. A type of brain scan called a PET scan is used measure 1) inflammation and 2) abnormal accumulation of a the amount of a certain protein fragment called beta-amyloid (plaques) in the brain. These are thought to be involved in Alzheimer's disease. The investigators will also perform brain MRI and do tests to measure the participants' memory and thinking.
NCT03119558 ↗	PET/MRI Evaluation of Cardiac Amyloid	Completed	Stanford University	Early Phase 1	2016-05-26	Cardiac amyloidosis is a disorder characterized by the deposition of abnormal proteins called amyloid in the heart tissue. This makes it difficult for the heart to function properly. The investigators wish to evaluate if the radiopharmaceutical 18F-Florbetaben (Neuraceq®) that targets beta amyloid can also identify cardiac amyloid deposition.

Clinical Trial Conditions for NEURACEQ

Condition Name

Condition Name for NEURACEQ
Intervention	Trials
Alzheimer Disease	2
Cardiac Amyloidosis	2
Multiple Myeloma	1
AL Amyloidosis	1

Condition MeSH

Condition MeSH for NEURACEQ
Intervention	Trials
Amyloidosis	3
Alzheimer Disease	3
Inflammation	2
Immunoglobulin Light-chain Amyloidosis	1

Clinical Trial Locations for NEURACEQ

Trials by Country

+

−

Trials by Country for NEURACEQ
Location	Trials
United States	4
Korea, Republic of	1

Trials by US State

+

−

Trials by US State for NEURACEQ
Location	Trials
New York	3
California	1

Clinical Trial Progress for NEURACEQ

Clinical Trial Phase

Clinical Trial Phase for NEURACEQ
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for NEURACEQ
Clinical Trial Phase	Trials
Completed	2
Enrolling by invitation	2
Not yet recruiting	1

Clinical Trial Sponsors for NEURACEQ

Sponsor Name

Sponsor Name for NEURACEQ
Sponsor	Trials
William Charles Kreisl	3
National Institute on Aging (NIA)	2
Stanford University	1

Sponsor Type

Sponsor Type for NEURACEQ
Sponsor	Trials
Other	5
NIH	2
Industry	1

Neuraceq: A Comprehensive Overview of Clinical Trials, Market Analysis, and Projections

Introduction to Neuraceq

Neuraceq, a diagnostic radiopharmaceutical developed by Life Molecular Imaging, is used in Positron Emission Tomography (PET) scans to detect β-amyloid neuritic plaques in the brains of patients with cognitive impairment, particularly those being evaluated for Alzheimer’s disease and other dementias.

Clinical Trials and Efficacy

Study Design and Outcomes

Neuraceq has been extensively evaluated in several clinical trials to assess its safety, efficacy, and diagnostic performance. These trials included three single-arm clinical studies that examined images from adults with a range of cognitive functions, including end-of-life patients who had agreed to post-mortem brain donation programs[3][4].

• Sensitivity and Specificity: The main study demonstrated high sensitivity (77.4%) and specificity (94.2%) for detecting β-amyloid plaques in the brain, with results closely reflecting autopsy findings[3][4].
• Interrater Agreement: The study also showed high interrater agreement among readers interpreting the PET scans, indicating reliability and reproducibility of the image interpretation methodology[1][3].
• Safety Profile: Clinical trials involving 872 subjects revealed a favorable safety profile with no serious adverse reactions. Common adverse reactions were mild to moderate and included injection site pain, erythema, and irritation[1][3].

Real-World Application

Neuraceq was also used in the IDEAS (Imaging Dementia—Evidence for Amyloid Scanning) study, where it was one of the amyloid PET tracers used. The study confirmed the high sensitivity and specificity of Neuraceq, with the highest interrater agreement among the tracers used[1].

Market Analysis

Current Market Status

The global Alzheimer's disease diagnostics market, in which Neuraceq plays a significant role, was estimated at USD 7.54 billion in 2023. North America dominates this market, driven by the high prevalence of Alzheimer’s disease and advanced research in biomarkers[5].

Reimbursement and Market Growth

Recent changes in reimbursement models in the US have significantly impacted Neuraceq’s market trajectory. Medicare Administrative Contractors now reimburse independent diagnostic testing facilities for Neuraceq scans, reducing out-of-pocket costs for healthcare providers and increasing accessibility[2].

• Forecasted Demand: With the approval of disease-modifying therapeutics like Leqembi and Kisunla, the demand for amyloid PET-CT diagnostics, including Neuraceq, is expected to rise. Forecasted demand suggests a significant increase in Neuraceq doses, potentially reaching 250,000 to 500,000 doses by 2029[2].

Value Proposition

Neuraceq delivers several key benefits:

• Accurate Detection: It provides accurate and specific detection of amyloid plaques, aiding in the diagnosis of Alzheimer’s disease and enabling patients to access disease-modifying drugs[2].
• Personalized Treatment: It supports more personalized treatment plans and ongoing disease monitoring, leading to better patient outcomes[2].
• Cost Reduction: By reducing the long-term burden on hospitals and the cost of chronic care, Neuraceq contributes to a more efficient healthcare system[2].

Market Projections

Growth Trajectory

The market for Neuraceq is expected to grow significantly due to several factors:

• Increasing Adoption: The growing demand for amyloid PET-CT diagnostics, driven by the increasing prevalence of Alzheimer’s disease and the availability of new therapeutics, is expected to drive Neuraceq’s adoption[2][5].
• Expanded Manufacturing: Life Molecular Imaging is expanding its manufacturing sites to meet the growing demand, which will enable the company to access a larger portion of the European market[2].

Financial Projections

• Revenue Growth: Neuraceq is forecasted to experience a year-over-year revenue growth of 160% to 190% from FY23 to FY24, with a target market share of 20% to 40% by 2029[2].
• Global Market Size: The global amyloid PET-CT market is projected to grow from $162 million in 2024 to $2.5 billion by 2029, driven by the increasing demand for diagnostic tools in the Alzheimer’s disease market[2].

Regulatory Approval and Use

Approval Status

Neuraceq has received market authorization from regulatory bodies such as Health Canada and the European Commission. The European Commission granted a marketing authorization for Neuraceq in 2014, and it is considered to have a favorable benefit/risk profile[3][4].

Clinical Use

Neuraceq is used as an adjunct to other diagnostic evaluations for patients with cognitive impairment. It is administered via intravenous injection about 90 minutes before the PET scan. The images are interpreted by physicians specially trained in reading PET scans with Neuraceq[4].

Limitations and Future Directions

Limitations of Use

While Neuraceq is highly effective in detecting β-amyloid plaques, it has several limitations:

• Diagnostic Confirmation: A positive Neuraceq scan does not establish the diagnosis of Alzheimer’s disease or other cognitive disorders on its own[3][4].
• Predictive Value: Neuraceq has not been established for predicting the development of dementia or monitoring responses to therapies[3][4].

Future Research

Future studies may focus on expanding the use of Neuraceq in predicting disease progression and monitoring treatment responses. Additionally, integrating Neuraceq with other biomarkers and diagnostic tools could enhance its utility in clinical practice.

Key Takeaways

• High Efficacy: Neuraceq has demonstrated high sensitivity and specificity in detecting β-amyloid plaques.
• Favorable Safety Profile: Clinical trials have shown a low risk of adverse reactions.
• Market Growth: Changes in reimbursement models and the approval of new therapeutics are driving increased demand.
• Regulatory Approval: Neuraceq has received market authorization from key regulatory bodies.
• Clinical Utility: It supports personalized treatment plans and ongoing disease monitoring.

FAQs

What is Neuraceq used for?

Neuraceq is used in PET scans to detect β-amyloid neuritic plaques in the brains of patients with cognitive impairment, particularly those being evaluated for Alzheimer’s disease and other dementias[3][4].

What are the key benefits of Neuraceq?

Neuraceq provides accurate and specific detection of amyloid plaques, supports personalized treatment plans, and aids in ongoing disease monitoring, leading to better patient outcomes and reduced long-term healthcare costs[2].

What are the common adverse reactions associated with Neuraceq?

The most common adverse reactions are injection site pain, erythema, and irritation, which are generally mild to moderate and of short duration[1][3].

How does Neuraceq compare to other amyloid PET tracers?

Neuraceq has shown the highest interrater agreement among the amyloid PET tracers used in the IDEAS study, indicating high reliability and reproducibility of its image interpretation methodology[1].

What are the future directions for Neuraceq?

Future studies may focus on expanding Neuraceq’s use in predicting disease progression and monitoring treatment responses, as well as integrating it with other biomarkers and diagnostic tools[3][4].

Sources

1. Neuraceq. Neuraceq. Retrieved October 11, 2024.
2. Life Molecular Imaging (LMI): Proposition and Value Articulation. Life Healthcare. Retrieved September 16, 2024.
3. Summary Basis of Decision for NeuraCeq. Health Canada. Retrieved 2024.
4. Neuraceq | European Medicines Agency (EMA). European Medicines Agency. Retrieved 2024.
5. Alzheimer's Disease Diagnostics Market Size Report, 2030. Grand View Research. Retrieved 2024.